Current Value
$46.401 Year Return
Current Value
$46.401 Year Return
Yahoo
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the C
Yahoo
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of 52,188 shares of common stock, 33,885 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 3,189 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 9 employees, whose employment commenced in December 2024
SeekingAlpha
Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy. Read my CYTK stock thesis here.
Yahoo
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). “With regulatory filings for aficamten already under review in
Finnhub
SOUTH SAN FRANCISCO - Cytokinetics, Incorporated today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals for the treatment of...
Yahoo
This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics originally sold those rights to Corxel in 2020. Additionally, it can reap royalties on future sales of the drug in Greater China.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MNOV | -12.81% | $97.60M | +33.11% | 0.00% |
CBOE | -11.99% | $20.20B | +9.90% | 1.22% |
ELF | -9.74% | $7.19B | -18.01% | 0.00% |
STG | -8.30% | $28.35M | -39.33% | 0.00% |
CATO | -8.21% | $73.73M | -49.37% | 14.37% |
QXO | -8.14% | $6.26B | -86.07% | 0.00% |
LITB | -8.13% | $27.03M | -76.89% | 0.00% |
CME | -7.07% | $82.63B | +15.91% | 4.55% |
SYPR | -7.01% | $48.81M | -0.47% | 0.00% |
BTCT | -6.38% | $20.85M | -11.24% | 0.00% |
MCK | -5.90% | $74.93B | +22.03% | 0.45% |
RILY | -5.86% | $139.66M | -80.13% | 22.57% |
CYCN | -5.29% | $8.78M | -11.72% | 0.00% |
K | -5.21% | $28.11B | +46.16% | 2.77% |
IMMP | -4.70% | $291.12M | -25.09% | 0.00% |
CORZ | -4.45% | $3.92B | +751.57% | 0.00% |
UFI | -4.44% | $109.06M | -13.48% | 0.00% |
XOS | -4.34% | $28.50M | -50.56% | 0.00% |
TCTM | -4.03% | $6.04M | -47.64% | 0.00% |
CHD | -2.80% | $25.13B | +6.31% | 1.12% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ACLX | 38.47% | $3.91B | +31.02% | 0.00% |
IRMD | 36.55% | $737.72M | +28.90% | 0.80% |
UVV | 36.41% | $1.28B | -14.52% | 4.80% |
FG | 36.32% | $5.23B | -0.26% | 2.15% |
JOE | 36.32% | $2.57B | -22.91% | 1.19% |
BPMC | 35.88% | $5.76B | +8.94% | 0.00% |
FOLD | 35.68% | $2.83B | -30.29% | 0.00% |
UPBD | 35.54% | $1.63B | -9.84% | 5.15% |
WS | 35.08% | $1.53B | +11.36% | 2.16% |
PHR | 35.02% | $1.65B | +21.29% | 0.00% |
BARK | 34.95% | $393.14M | +144.40% | 0.00% |
TITN | 34.86% | $323.76M | -48.42% | 0.00% |
SYNA | 34.66% | $3.15B | -26.18% | 0.00% |
BECN | 34.58% | $6.42B | +21.99% | 0.00% |
FLIC | 34.47% | $259.50M | -10.08% | 7.57% |
LECO | 34.44% | $10.46B | -11.35% | 1.59% |
APLS | 34.43% | $4.10B | -52.42% | 0.00% |
LGND | 34.30% | $2.09B | +50.37% | 0.00% |
MC | 34.30% | $5.27B | +39.11% | 3.34% |
RCKT | 34.26% | $1.25B | -59.57% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ASPS | -0.15% | $25.79M | -67.45% | 0.00% |
CYD | 0.17% | $431.87M | +26.44% | 3.67% |
LMT | 0.25% | $111.13B | +2.95% | 2.73% |
MAGN | 0.29% | $660.53M | -5.41% | 0.00% |
SBUX | 0.30% | $104.99B | -0.96% | 2.52% |
GRAL | -0.33% | $593.39M | +3.88% | 0.00% |
NVDA | -0.38% | $3.43T | +157.79% | 0.05% |
MANU | -0.45% | $2.81B | -20.61% | 0.00% |
SAVA | -0.46% | $135.91M | -88.36% | 0.00% |
FATBB | -0.49% | $80.25M | -14.94% | 11.99% |
SMCI | -0.54% | $19.10B | -4.76% | 0.00% |
LFVN | 0.58% | $250.13M | +246.70% | 0.68% |
PULM | 0.58% | $21.88M | +193.63% | 0.00% |
FENG | -0.59% | $13.86M | +75.69% | 0.00% |
ADM | -0.62% | $23.85B | -28.11% | 3.98% |
GALT | -0.66% | $70.41M | -40.21% | 0.00% |
CL | 0.70% | $71.46B | +8.58% | 2.29% |
LRN | 0.71% | $4.75B | +88.13% | 0.00% |
VZ | -0.74% | $163.92B | -0.36% | 7.06% |
KNOP | -0.75% | $213.80M | +3.63% | 1.74% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -31.05% | $195.31M | 0.85% |
TAIL | -21.12% | $65.56M | 0.59% |
CORN | -12.95% | $63.58M | 0.2% |
GBIL | -12.11% | $5.84B | 0.12% |
WEAT | -8.20% | $119.67M | 0.28% |
USDU | -8.19% | $379.83M | 0.5% |
CTA | -4.84% | $483.80M | 0.76% |
TPMN | -4.39% | $41.62M | 0.65% |
UUP | -4.38% | $603.95M | 0.77% |
FLTR | -4.28% | $1.95B | 0.14% |
XBIL | -3.76% | $641.82M | 0.15% |
SGOV | -3.63% | $30.65B | 0.09% |
XHLF | -3.63% | $939.75M | 0.03% |
MINT | -3.00% | $11.98B | 0.35% |
ULST | -2.74% | $539.53M | 0.2% |
IVOL | -2.57% | $451.42M | 1.02% |
DBB | -2.37% | $110.21M | 0.77% |
XONE | -1.66% | $540.53M | 0.03% |
SEIX | -1.57% | $300.05M | 0.62% |
UNG | -1.30% | $746.57M | 1.06% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
AGZD | -0.06% | $142.56M | 0.23% |
EQLS | -0.41% | $8.97M | 1% |
TBLL | -0.54% | $2.00B | 0.08% |
BUXX | 0.63% | $190.00M | 0.25% |
SOYB | 0.78% | $24.83M | 0.22% |
DBA | 0.83% | $794.04M | 0.93% |
BIL | -0.97% | $36.56B | 0.1356% |
BILS | 0.98% | $3.33B | 0.1356% |
IBTF | 1.00% | $2.23B | 0.07% |
TBIL | -1.01% | $4.78B | 0.15% |
KMLM | -1.07% | $334.70M | 0.9% |
UNG | -1.30% | $746.57M | 1.06% |
SEIX | -1.57% | $300.05M | 0.62% |
XONE | -1.66% | $540.53M | 0.03% |
IBTG | 1.90% | $1.63B | 0.07% |
IBMO | 2.03% | $508.35M | 0.18% |
ICSH | 2.13% | $5.26B | 0.08% |
FTSM | 2.26% | $6.16B | 0.45% |
DBB | -2.37% | $110.21M | 0.77% |
IVOL | -2.57% | $451.42M | 1.02% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 59.83% | $270.13M | 0% |
XBI | 50.87% | $6.39B | 0.35% |
IBB | 48.32% | $6.59B | 0.45% |
IWC | 45.35% | $965.33M | 0.6% |
PBE | 44.83% | $251.02M | 0.58% |
PTH | 44.36% | $122.57M | 0.6% |
RYLD | 43.32% | $1.47B | 0.6% |
ISCG | 42.64% | $641.73M | 0.06% |
IWM | 42.34% | $72.22B | 0.19% |
VTWO | 42.31% | $12.40B | 0.1% |
GNOM | 42.22% | $71.12M | 0.5% |
IWO | 42.16% | $12.83B | 0.24% |
FBT | 41.88% | $1.13B | 0.56% |
VXF | 41.47% | $21.57B | 0.06% |
VBK | 40.91% | $19.73B | 0.07% |
NUSC | 40.90% | $1.24B | 0.31% |
ESML | 40.88% | $1.89B | 0.17% |
IWN | 40.79% | $12.27B | 0.24% |
VB | 40.60% | $63.75B | 0.05% |
FXH | 40.55% | $1.07B | 0.62% |